{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:02:58Z","timestamp":1773849778909,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ratchadaphisek Somphot Endowment Fund of hepatic fibrosis and cirrhosis research unit","award":["GRU 6105530009-1"],"award-info":[{"award-number":["GRU 6105530009-1"]}]},{"name":"Research Chair Grant from the National Science and Technology Development Agency","award":["P-15-50004"],"award-info":[{"award-number":["P-15-50004"]}]},{"name":"Ratchadapisek Sompoch Research Grant","award":["RA59\/074"],"award-info":[{"award-number":["RA59\/074"]}]},{"name":"Ratchadapisek Sompoch Research Grant","award":["RA60\/101"],"award-info":[{"award-number":["RA60\/101"]}]},{"name":"Thai Association for the Study of the Liver"},{"name":"Center of Excellence in Clinical Virology of Chulalongkorn University and King Chulalongkorn Memorial Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Vitamin D (VD) is important in hepatic fibrogenesis in animal models and human studies. VD deficiency is associated with liver fibrosis progression. Metabolic dysfunction of the liver, as an intermediate organ for VD metabolism, contributes partly to this deficiency. We hypothesized that improving hepatic fibrosis and inflammation in chronic hepatitis C (CHC) patients after eradication with direct-acting antivirals (DAA) would increase 25-hydroxyVD [25(OH)VD] levels.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Eighty CHC patients (17 chronic hepatitis, and 63 cirrhosis) were enrolled. Baseline characteristics, hepatitis C viral load (VL), genotypes, liver enzymes and liver stiffness measurements (LSM) were assessed at baseline. Blood samples for 25(OH)VD and the procollagen type III N-terminal peptide (P3NP) were collected at baseline, 24 and 48\u00a0weeks. LSMs were re-evaluated at 48\u00a0weeks. Serum 25(OH)VD levels\u2009&lt;\u200930\u00a0ng\/mL were defined as VD insufficiency\/deficiency. Paired <jats:italic>t<\/jats:italic>-tests were used for statistical analyses.\n<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Among 80 patients, the mean age was 57.7\u2009\u00b1\u200910.5\u00a0years, and 52.5% were men. The mean VL was 6.1\u2009\u00b1\u20090.7 logIU\/mL with genotype 1 predominance (55%). All patients achieved sustained virological response. The alanine aminotransferase levels decreased from 79.9\u2009\u00b1\u200953.3 U\/L at baseline to 25.7\u2009\u00b1\u200917.2 and 22.3\u2009\u00b1\u200911.0 U\/L at 24 and 48\u00a0weeks, respectively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The mean LSM decreased from 19.2\u2009\u00b1\u200915.3 to 11.7\u2009\u00b1\u20098.0\u00a0kPa at 48\u00a0weeks (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The P3NP levels decreased from 43.6\u2009\u00b1\u200922.0\u00a0ng\/mL before treatment to 35.7\u2009\u00b1\u200921.1 and 29.4\u2009\u00b1\u200915.0\u00a0ng\/mL at 24 and 48\u00a0weeks, respectively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The proportions of VD insufficiency\/deficiency were 72.5%, 91.3%, and 86.5% at baseline, 24 and 48\u00a0weeks, respectively. The 25(OH)VD levels decreased from 26.3\u2009\u00b1\u200910.7\u00a0ng\/mL at baseline to 20.8\u2009\u00b1\u20098.1 and 20.8\u2009\u00b1\u20098.5\u00a0ng\/mL at 24 and 48\u00a0weeks, respectively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Curative treatment with DAA attenuated the liver stiffness and inflammation but did not improve VD levels. Over 80% of patients remained VD insufficient\/deficient. Whether VD replacement during and after DAA therapy can improve hepatic fibrosis remains unclear.\n<\/jats:p>\n<jats:p><jats:italic>Trial registration<\/jats:italic> The Thai Clinical Trial Registry as TCTR20161025001 (31 October 2016). <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.in.th\/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=2136\">http:\/\/www.clinicaltrials.in.th\/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=2136<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12876-020-01485-8","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T06:02:39Z","timestamp":1602914559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy"],"prefix":"10.1186","volume":"20","author":[{"given":"Supachaya","family":"Sriphoosanaphan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kessarin","family":"Thanapirom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirinporn","family":"Suksawatamnuay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panarat","family":"Thaimai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukanya","family":"Sittisomwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanokwan","family":"Sonsiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nunthiya","family":"Srisoonthorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicha","family":"Teeratorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nattaporn","family":"Tanpowpong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bundit","family":"Chaopathomkul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sombat","family":"Treeprasertsuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Poovorawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1357-9547","authenticated-orcid":false,"given":"Piyawat","family":"Komolmit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,17]]},"reference":[{"issue":"3","key":"1485_CR1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"MF Holick","year":"2007","unstructured":"Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266\u201381.","journal-title":"N Engl J Med"},{"issue":"1","key":"1485_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41467-017-02662-2","volume":"9","author":"X Jiang","year":"2018","unstructured":"Jiang X, O'Reilly PF, Aschard H, Hsu YH, Richards JB, Dupuis J, Ingelsson E, Karasik D, Pilz S, Berry D, et al. Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels. Nat Commun. 2018;9(1):260.","journal-title":"Nat Commun"},{"issue":"4","key":"1485_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jhep.2012.04.033","volume":"57","author":"MT Kitson","year":"2012","unstructured":"Kitson MT, Roberts SK. D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol. 2012;57(4):897\u2013909.","journal-title":"J Hepatol"},{"issue":"3","key":"1485_CR4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.cell.2013.03.028","volume":"153","author":"N Ding","year":"2013","unstructured":"Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, Coulter S, He M, Scott C, et al. A vitamin D receptor\/SMAD genomic circuit gates hepatic fibrotic response. Cell. 2013;153(3):601\u201313.","journal-title":"Cell"},{"issue":"3","key":"1485_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1365-2265.2011.04261.x","volume":"76","author":"M Hewison","year":"2012","unstructured":"Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf). 2012;76(3):315\u201325.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"1485_CR6","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine S. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1485_CR7","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/hep.23489","volume":"51","author":"S Petta","year":"2010","unstructured":"Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, Cabibi D, Licata G, Porcasi R, Marchesini G, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology (Baltimore, MD). 2010;51(4):1158\u201367.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"3","key":"1485_CR8","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"M Charlton","year":"2015","unstructured":"Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, Terrault NA, O'Leary JG, Vargas HE, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649\u201359.","journal-title":"Gastroenterology"},{"issue":"9865","key":"1485_CR9","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (London, England). 2013;381(9865):468\u201375.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"1485_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"J-M Pawlotsky","year":"2018","unstructured":"Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461\u2013511.","journal-title":"J Hepatol"},{"issue":"27","key":"1485_CR11","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"1485_CR12","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/jvh.12180","volume":"21","author":"P Labarga","year":"2014","unstructured":"Labarga P, Fernandez-Montero JV, Barreiro P, Pinilla J, Vispo E, de Mendoza C, Plaza Z, Soriano V. Changes in liver fibrosis in HIV\/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy. J Viral Hepat. 2014;21(7):475\u20139.","journal-title":"J Viral Hepat"},{"issue":"7","key":"1485_CR13","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/apt.14554","volume":"47","author":"T Tada","year":"2018","unstructured":"Tada T, Kumada T, Toyoda H, Sone Y, Takeshima K, Ogawa S, Goto T, Wakahata A, Nakashima M, Nakamuta M, et al. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy. Aliment Pharmacol Ther. 2018;47(7):1012\u201322.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"1485_CR14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.jhep.2010.08.036","volume":"54","author":"CM Lange","year":"2011","unstructured":"Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, Herrmann E, Badenhoop K, Zeuzem S, Sarrazin C. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol. 2011;54(5):887\u201393.","journal-title":"J Hepatol"},{"issue":"7","key":"1485_CR15","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1485_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","volume":"128","author":"L Castera","year":"2005","unstructured":"Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Ledinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343\u201350.","journal-title":"Gastroenterology"},{"issue":"4","key":"1485_CR17","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.cgh.2014.12.014","volume":"13","author":"NH Afdhal","year":"2015","unstructured":"Afdhal NH, Bacon BR, Patel K, Lawitz EJ, Gordon SC, Nelson DR, Challies TL, Nasser I, Garg J, Wei LJ, et al. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol. 2015;13(4):772\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"1485_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C. J Hepatol. 2018;69(2):461\u2013511.","journal-title":"J Hepatol"},{"issue":"20","key":"1485_CR19","doi-asserted-by":"publisher","first-page":"7711","DOI":"10.1073\/pnas.0402490101","volume":"101","author":"JB Cheng","year":"2004","unstructured":"Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A. 2004;101(20):7711\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"39","key":"1485_CR20","doi-asserted-by":"publisher","first-page":"15650","DOI":"10.1073\/pnas.1315006110","volume":"110","author":"JG Zhu","year":"2013","unstructured":"Zhu JG, Ochalek JT, Kaufmann M, Jones G, Deluca HF. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proc Natl Acad Sci U S A. 2013;110(39):15650\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1485_CR21","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/hep.24752","volume":"55","author":"GT Everson","year":"2012","unstructured":"Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Lauriski S, Curto TM, Stoddard A, Wright EC. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology (Baltimore, MD). 2012;55(4):1019\u201329.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"1485_CR22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1186\/1471-2458-11-853","volume":"11","author":"LO Chailurkit","year":"2011","unstructured":"Chailurkit LO, Aekplakorn W, Ongphiphadhanakul B. Regional variation and determinants of vitamin D status in sunshine-abundant Thailand. BMC Public Health. 2011;11:853.","journal-title":"BMC Public Health"},{"issue":"9736","key":"1485_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0140-6736(10)60588-0","volume":"376","author":"TJ Wang","year":"2010","unstructured":"Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (London, England). 2010;376(9736):180\u20138.","journal-title":"Lancet (London, England)"},{"issue":"3","key":"1485_CR24","doi-asserted-by":"publisher","first-page":"e0173263","DOI":"10.1371\/journal.pone.0173263","volume":"12","author":"K Thanapirom","year":"2017","unstructured":"Thanapirom K, Suksawatamnuay S, Sukeepaisarnjareon W, Tanwandee T, Charatcharoenwitthaya P, Thongsawat S, Leerapun A, Piratvisuth T, Boonsirichan R, Bunchorntavakul C, et al. Genetic variation in the vitamin D pathway CYP2R1 gene predicts sustained HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon: a multicenter study. PLoS ONE. 2017;12(3):e0173263.","journal-title":"PLoS ONE"},{"issue":"1","key":"1485_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12876-017-0613-x","volume":"17","author":"K Thanapirom","year":"2017","unstructured":"Thanapirom K, Suksawatamnuay S, Sukeepaisarnjaroen W, Tangkijvanich P, Treeprasertsuk S, Thaimai P, Wasitthankasem R, Poovorawan Y, Komolmit P. Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients. BMC Gastroenterol. 2017;17(1):54.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"1485_CR26","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/hep.26488","volume":"58","author":"H Farnik","year":"2013","unstructured":"Farnik H, Bojunga J, Berger A, Allwinn R, Waidmann O, Kronenberger B, Keppler OT, Zeuzem S, Sarrazin C, Lange CM. Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients. Hepatology (Baltimore, MD). 2013;58(4):1270\u20136.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"1485_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12876-019-1004-2","volume":"19","author":"YC Hu","year":"2019","unstructured":"Hu YC, Wang WW, Jiang WY, Li CQ, Guo JC, Xun YH. Low vitamin D levels are associated with high viral loads in patients with chronic hepatitis B: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):84.","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"1485_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/apt.13244","volume":"42","author":"GY Guo","year":"2015","unstructured":"Guo GY, Shi YQ, Wang L, Ren X, Han ZY, Guo CC, Cui LN, Wang JB, Zhu J, Wang N, et al. Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis. Aliment Pharmacol Ther. 2015;42(2):221\u201330.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"1485_CR29","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1007\/s10620-014-3267-3","volume":"59","author":"C Efe","year":"2014","unstructured":"Efe C, Kav T, Aydin C, Cengiz M, Imga NN, Purnak T, Smyk DS, Torgutalp M, Turhan T, Ozenirler S, et al. Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis. Dig Dis Sci. 2014;59(12):3035\u201342.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"1485_CR30","doi-asserted-by":"publisher","first-page":"e0174608","DOI":"10.1371\/journal.pone.0174608","volume":"12","author":"P Komolmit","year":"2017","unstructured":"Komolmit P, Charoensuk K, Thanapirom K, Suksawatamnuay S, Thaimai P, Chirathaworn C, Poovorawan Y. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLoS ONE. 2017;12(4):e0174608.","journal-title":"PLoS ONE"},{"issue":"12","key":"1485_CR31","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1136\/gut.2010.234666","volume":"60","author":"S Abramovitch","year":"2011","unstructured":"Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Ben Tov A, Brazowski E, Reif S. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut. 2011;60(12):1728\u201337.","journal-title":"Gut"},{"issue":"1","key":"1485_CR32","doi-asserted-by":"publisher","first-page":"8905","DOI":"10.1038\/s41598-017-09512-7","volume":"7","author":"P Komolmit","year":"2017","unstructured":"Komolmit P, Kimtrakool S, Suksawatamnuay S, Thanapirom K, Chattrasophon K, Thaimai P, Chirathaworn C, Poovorawan Y. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: a randomized, double-blind, placebo-controlled study. Sci Rep. 2017;7(1):8905.","journal-title":"Sci Rep"},{"issue":"11","key":"1485_CR33","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/hep4.1228","volume":"2","author":"JJ Pan","year":"2018","unstructured":"Pan JJ, Bao F, Du E, Skillin C, Frenette CT, Waalen J, Alaparthi L, Goodman ZD, Pockros PJ. Morphometry confirms fibrosis regression from sustained virologic response to direct-acting antivirals for hepatitis C. Hepatol Commun. 2018;2(11):1320\u201330.","journal-title":"Hepatol Commun"},{"issue":"11","key":"1485_CR34","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1097\/MEG.0000000000000964","volume":"29","author":"E Dolmazashvili","year":"2017","unstructured":"Dolmazashvili E, Abutidze A, Chkhartishvili N, Karchava M, Sharvadze L, Tsertsvadze T. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience. Eur J Gastroenterol Hepatol. 2017;29(11):1223\u2013300.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"1485_CR35","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/hep.22056","volume":"47","author":"A Sagir","year":"2008","unstructured":"Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology (Baltimore, MD). 2008;47(2):592\u20135.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"6","key":"1485_CR36","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1365-2036.2011.04765.x","volume":"34","author":"C Hezode","year":"2011","unstructured":"Hezode C, Castera L, Roudot-Thoraval F, Bouvier-Alias M, Rosa I, Roulot D, Leroy V, Mallat A, Pawlotsky JM. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther. 2011;34(6):656\u201363.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1485_CR37","first-page":"429","volume":"35","author":"MJ Nielsen","year":"2015","unstructured":"Nielsen MJ, Veidal SS, Karsdal MA, Orsnes-Leeming DJ, Vainer B, Gardner SD, Hamatake R, Goodman ZD, Schuppan D, Patel K. Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int Off J Int Assoc Study Liver. 2015;35(2):429\u201337.","journal-title":"Liver Int Off J Int Assoc Study Liver"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01485-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-020-01485-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01485-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T23:24:50Z","timestamp":1634426690000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-020-01485-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,17]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1485"],"URL":"https:\/\/doi.org\/10.1186\/s12876-020-01485-8","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,17]]},"assertion":[{"value":"11 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Institutional Review Board of the Faculty of Medicine of Chulalongkorn University (IRB No.: 424\/59). The study was registered with the Thai Clinical Trial Registry (TCTR20161025001) on 31 October 2016. All participants provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"346"}}